Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.53 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6307072 | 1.00 | SIGMAR1 (0.53) | SIGMAR1CCR3ALDH1A1NPC1RAB9A | |
| SCHEMBL6304033 | 0.94 | SIGMAR1 (0.58) | SIGMAR1CCR3ALDH1A1POLBLMNA | |
| SCHEMBL6304036 | 0.94 | SIGMAR1 (0.58) | SIGMAR1CCR3ALDH1A1POLBLMNA | |
| SCHEMBL6303615 | 0.89 | SIGMAR1 (0.53) | SIGMAR1CCR3POLBMEN1KMT2A | |
| SCHEMBL6303612 | 0.89 | SIGMAR1 (0.53) | SIGMAR1CCR3POLBMEN1KMT2A | |
| SCHEMBL6304087 | 0.89 | SIGMAR1 (0.53) | SIGMAR1CCR3ALDH1A1NPC1 | |
| SCHEMBL6304092 | 0.89 | SIGMAR1 (0.53) | SIGMAR1CCR3ALDH1A1NPC1 | |
| SCHEMBL6307234 | 0.89 | SIGMAR1 (0.50) | SIGMAR1CCR3ALDH1A1POLBMEN1 | |
| SCHEMBL6307237 | 0.89 | SIGMAR1 (0.50) | SIGMAR1CCR3ALDH1A1POLBMEN1 | |
| SCHEMBL6303784 | 0.88 | OPRK1 (0.47) | CCR3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6977265-B2 | Piperidine CCR-3 receptor antagonists | ROCHE PALO ALTO LLC (US) | 2005-12-20 | — | — | US | disclosed |
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | SYNTEX (U.S.A.) LLC | 2003-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229121-A1 | Piperidine CCR-3 receptor antagonists | CCR1, CCR3, CCRL2 | SIGMAR1 140/4885CCR3 2/4885ALDH1A1 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.